Is a whole-body MRI scan (Prenuvo, Neko Health) worth it for a healthy person?

Short version: if you feel fine and your risk is average, there is no good evidence this scan helps you live longer. And here is the part that surprises people. It is not that a big trial tested it and came up empty. It is that no randomized trial has ever tested whether whole-body MRI screening reduces death from cancer or any cause. So the headline benefit hangs on a gap in the evidence, not on a result that proved it works. Those are two very different things.

Look at how thin the ground is. One 2019 review pulled together 12 studies covering 5,373 people with no symptoms ^[1]. Not one of them checked, over the long run, what actually happened to the people who got a clean result. A 2026 review goes further. It says scanning healthy people for many diseases at once breaks with the basic rules of good screening, and that the benefit just is not there in the population data ^[6].

Meanwhile the marketing wave is rolling in. Prenuvo (US) opened its first European clinic in London in 2025. Neko Health, the Swedish company co-founded by Spotify's Daniel Ek, is pushing in too. But its product is not even an MRI: it is a sensor-based body scan plus blood markers, priced far lower (around £299 in London). Slick branding, calm clinics, the promise of catching cancer before it catches you.

Here is the catch. The actual yield is tiny. Across people with no symptoms, the scans turn up cancer in about 1.57% of them, pooled from a 2025 meta-analysis of 10 studies and 9,024 people ^[2]. That small signal gets buried under everything else the scan lights up.

So the trade is easy to say and hard to swallow. You buy a small chance of catching a real cancer. Right next to it, you buy a near-certain pile of incidental findings (random stuff the scan spots that has nothing to do with why you came). A clean scan still misses fast-growing tumors and cancers in hollow organs. And an abnormal scan is far more likely to kick off a round of tests than to save your life. This is not the clean peace-of-mind purchase the website sells.

Short answer: a whole-body MRI is good at seeing solid masses without radiation (tumors in the kidney or liver, aneurysms, various lumps), but it is poor at the cancers that kill the most people. Early lung and early colorectal cancer slip past it, so a normal scan cannot replace mammography, colonoscopy, or the Pap/HPV test. Here is the detail.

MRI is genuinely good at some things. It pictures soft tissue beautifully, and it uses no radiation at all. It can spot certain tumors in solid organs, lesions in the kidney or liver, aneurysms (a ballooning weak spot in the wall of a blood vessel), and various lumps. If a tumor is a solid lump sitting in an organ the MRI scans well, the scan will usually see it.

Notice the gap, though. Seeing something is not the same as catching a deadly cancer early enough to change how things go for you.

Now the blind spots, and these are the ones that break the whole screening promise. Early lung cancer? Caught poorly. Early colon and colorectal cancer? Caught poorly. Most trouble in hollow organs (your lungs, your bowel, your bladder, anything with air or an open cavity) slips right past a whole-body MRI. And those are exactly the cancers that kill the most people.

Which is the whole reason the scan cannot stand in for the screening that does have evidence behind it: mammography, colonoscopy, and the Pap or HPV test. The expert reviews say the same thing. Whole-body MRI is a step away from proven screening, not a step up from it ^{[6, 11]}.

On safety, give MRI its due. A CT scan or a coronary calcium (CAC) scan uses ionizing radiation. MRI does not, so there is no radiation dose at all. That advantage is real. But the main harm here was never radiation in the first place. It is the chain of follow-up the scan sets off, which is what the next section is about.

So where does this leave you? Think of whole-body MRI as extra imaging that lines up badly with the cancers most likely to kill you. A clean result can hand you false comfort about lung and bowel cancer in particular, the two areas where MRI is weakest. A clean scan is not a clean bill of health, and it does not cancel the age-appropriate screening you already qualify for.

Almost everyone lights up. In people with no symptoms, about 95% of scans show at least one abnormal finding, and roughly 91% of those findings mean nothing for your health ^[6]. Read that twice. Out of every 20 people scanned, 19 get told about something. And for nearly all of them, that something turns out to be a non-event.

Keep the numbers honest, though, because they are not all the same number. The 95% and 91% cover any finding at all, and the ones that do not matter. The slice that actually deserves a closer look is smaller. The 2019 review put the rate of critical-plus-uncertain findings at about 32% (95% CI 18 to 50%) ^[1]. Do not mix the two up. So roughly a third of scans turn up something a radiologist wants to look at again.

How many of those second looks turn out to be real? Here the data get leaky. The pooled false-positive rate came out at about 16% (95% CI 1.9 to 65.8%), and only about 12.6% of the critical or uncertain findings were ever checked to see if they were real ^[1]. Those huge ranges are not a footnote. They are the whole point: the evidence underneath is weak and all over the place. A 2018 BMJ meta-analysis ^[9] and a 2018 umbrella review ^[13] back up just how common these random findings are across body imaging.

Now the real-world harm, close to home. In the German SHIP population study, 3,371 people got scanned ^[3]. 30.3% were told about an incidental finding, most of them tumor-related. Of the biopsies that followed, 62.1% found no cancer or tumor at all. That is overdiagnosis you can touch: real needles, real tissue taken out, mostly chasing harmless spots.

So, the honest now-what. One finding sets off more MRIs, blood tests, specialist visits, and sometimes biopsies that carry their own risk of complications. Most of that is chasing something that was never going to hurt you. The money, the lost time, and the worry are not rare side effects. They are the near-certain price of a ticket.

The answer is short: the big medical societies do not back whole-body MRI screening for average-risk people who feel fine. The American College of Radiology says so flat out. Its 2023 Statement on Screening Total Body MRI says there is not enough evidence to recommend scanning the whole body in people with no risk factors or family history, and that it should not be offered as preventive screening outside research ^[11]. The Royal Australian and New Zealand College of Radiologists came out with a 2024 position statement on whole-body MRI screening in low-risk patients that lands in exactly the same place ^[8].

This is not gatekeeping for its own sake. The reason is the harm profile you have already met: false positives, incidentalomas (harmless lumps the scan stumbles on), overdiagnosis, and no proven benefit for how long you live. That is exactly why the societies hold back, and reviews flag the same harms and the same break with good screening practice ^{[12, 6]}. A test that flags one in three people, barely checks whether any of it is real, and has never been shown to save a single life is just a hard thing to recommend with a straight face.

One fair caveat, because honest skepticism cuts both ways. The evidence on psychological harm is mixed, not damning. A 2025 study followed 121 people with no symptoms, all of whom had abnormal findings, and saw only a small short-term dip in mood, with no clear lasting psychological harm ^[7]. But the long-term group shrank to 61 people, so treat it as weak evidence either way. It is not strong reassurance, and it is not proof of lasting damage. Telling someone they have an abnormal finding is not automatically traumatic. It is not free, either.

A DACH note, kept honest. We could not find a clear, primary position statement from the Deutsche Roentgengesellschaft (DRG), Germany's radiology society, on self-pay whole-body MRI screening for this guide. So the picture here leans on the ACR (2023) ^[11] and RANZCR (2024) ^[8]. There is no made-up quote from a German society, because we could not verify one.

There is one group this genuinely helps, and it is small: people who inherited a high-risk cancer syndrome. The clearest example is Li-Fraumeni syndrome, which comes from an inherited glitch in a gene called TP53 (a gene whose normal job is to stop cells from turning cancerous). That glitch pushes lifetime cancer risk way up. For these carriers, whole-body MRI surveillance actually has solid evidence behind it.

And the numbers shift hard. A 2024 meta-analysis pooled 11 studies covering 703 TP53 carriers: the first MRI confirmed cancer in about 18% of suspicious spots, picked up early-stage cancer in around 6%, and caught 41 of 46 cancers at an early stage ^[4]. A second 2024 meta-analysis of 506 carriers found cancer in about 7% of people, pooled ^[5], and a 2017 JAMA Oncology meta-analysis backs that up ^[10]. Now set that next to the 1.57% in average-risk people. Same scan, four to seven times more useful.

Why does this hold up for one group but not the other? It comes down to your odds going in, not anything magic about the machine. In a group where cancer really is common, the same test flips from mostly false alarms to real early catches. That is also why the story you hear at a party does not transfer. Someone telling you the scan found their cousin's tumor may be telling the truth, but it says nothing about a healthy buyer with average risk. The cousin's odds were never your odds.

So who should skip it? Average-risk adults who feel fine and carry no qualifying inherited syndrome. That is exactly who the marketing chases, and exactly who has the weakest case for buying. And if you have real symptoms (a lump, pain that will not quit, bleeding), you do not need a screening scan at all. You need a targeted work-up through a doctor, which is a different and faster road.

One last framing. If you carry a known high-risk inherited mutation (one you were born with), the surveillance is a medical call you make with a genetics or oncology team, and it is often covered as care. It is not a self-pay scan you book online between a sauna session and a smoothie.

In Germany, Austria, and Switzerland, you pay for this scan yourself. In Germany it is an IGeL (Individuelle Gesundheitsleistung, a self-pay service you cover out of pocket), and it runs roughly 1,500 to 3,000 EUR per scan (Prenuvo's London clinic lists about £2,499). Statutory insurance (GKV) will not cover it for average-risk screening. Neko Health's body-scan-plus-blood model is set up and priced differently, and it usually comes in cheaper than a standalone Prenuvo-style MRI. Read the no-coverage decision as a signal, not a loophole. When the GKV declines to pay, it is echoing the guidelines: this is not evidence-based screening.

The sticker price is the smaller bill, by the way. The real spending starts when an incidental finding triggers follow-up scans, specialist visits, and biopsies, a lot of it out of pocket too. Tie it back to the German SHIP study: 62.1% of biopsies there found nothing cancerous, yet every one cost money, cost time, and carried its own risk of complications ^[3]. The scan price quietly hides the real total.

Then there is your data, and this part deserves real attention. A whole-body image of you is sensitive health data. Add blood markers and AI analysis, the way Neko does, and the stakes go up. So ask honestly: where do the scans and the AI processing actually happen, on US servers or EU servers, for Prenuvo and for Neko? What exactly are you agreeing to? How long do they keep your images, and who can get at them? Under GDPR (Europe's data-protection law) these are not idle questions. The research on whether the scan works does not answer them, so treat them as things to ask the provider before you book, not as a verdict.

Honest bottom line for a self-pay buyer. If you are an average-risk, healthy adult, your money does more for you somewhere else. Finish the screening you actually qualify for under the guidelines: mammography, colonoscopy, cervical screening, plus blood markers that have evidence behind them. Save whole-body MRI for the inherited-syndrome group or a research study. That is where the scan earns its keep, and everywhere else is where it does not.